Results 11 to 20 of about 8,165 (189)

High-Throughput mRNA Sequencing Reveals Potential Therapeutic Targets of Febuxostat in Secondary Injury After Intracerebral Hemorrhage

Frontiers in Pharmacology, 2022
Febuxostat is a urate-lowering medication for the treatment of patients with gout. This study was performed to elucidate the effects and underlying mechanisms of febuxostat on neuronal injury induced by intracerebral hemorrhage (ICH) in mice. The results
Xueyan Wang, Chenyu Zhang, Chenyu Zhang, Yuwen Li, Yuwen Li, Ting Xu, Ting Xu, Jin Xiang, Yang Bai, Ying Zhang, Qi Wang, Tiejun Zhang, Linchuan Liao   +12 more
doaj   +1 more source

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2

Antioxidants, 2023
Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS).
Yoshiki Higa, Masahiro Hiasa, Hirofumi Tenshin, Emiko Nakaue, Mariko Tanaka, Sooha Kim, Motosumi Nakagawa, So Shimizu, Kotaro Tanimoto, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Ryohei Sumitani, Tomoko Maruhashi, Hiroki Yamagami, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka, Masahiro Abe   +21 more
doaj   +1 more source

Impact of urate-lowering therapy on quality of life indicators in patients with gout

Современная ревматология, 2021
Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ...
M. N. Chikina, O. V. Zhelyabina, M. S. Eliseev   +2 more
doaj   +1 more source

Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity [PDF]

, 2014
Aims Obesity is a risk factor for diabetes and cardiovascular diseases, with the incidence of these disorders becoming epidemic. Pathogenic responses to obesity have been ascribed to adipose tissue (AT) dysfunction that promotes bioactive mediator ...
Baust, Jeff, Bonacci, Gustavo Roberto, Cantu Medellin, Nadiezhda, Champion, Hunter C., Croix, Claudette M. St., Devlin, Jason E., Freeman, Bruce A., Frisbee,Jefferson C., Gladwin, Mark T., Golin Bisello, Franca, Gor, Sonia, Kelley, Eric E., Khoo, Nicholas K.H., Watkins, Simon C., Weidert, Eric R.   +14 more
core   +1 more source

Febuxostat: a new drug for an old disease. Do we really need it?

Italian Journal of Medicine, 2013
BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration.
Giovanni Gulli, Luigi de Filippis
doaj   +1 more source

Pharmacology and clinical drug candidates in redox medicine [PDF]

, 2015
SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I, Cuadrado, Antonio, Dao, V Thao-Vi, Di Lisa, Fabio, Ghezzi, Pietro, Jaquet, Vincent, Kaludercic, Nina, Maghzal, Ghassan J, Robledinos-Anton, Natalia, Schmidt, Harald H H W, Seredenina, Tamara, Stocker, Roland   +11 more
core   +3 more sources

The current treatment strategy for gouty arthritis

Современная ревматология, 2018
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA).
M. S. Petrova, М. M. Musiychuk, V. I. Mazurov   +2 more
doaj   +1 more source

Evaluation of analgesic activity of allopurinol and febuxostat in experimental analgesic models in mice

Indian Journal of Pain, 2015
Background: Allopurinol and febuxostat are xanthine oxidase inhibitors which are used in the treatment of hyperuricemia and gout. Pain is one of the important symptoms in gout patients.
Promod D Shankpal, J H Hotwani, Kunal A Chitnis, Dnyanesh S Tadke, Vijay R Kokani   +4 more
doaj   +1 more source

Febuxostat-induced acute liver injury [PDF]

, 2016
Febuxostat is a unique xanthine oxidase inhibitor that was approved for the prevention of gout in the United States in 2009. Unlike allopurinol, febuxostat is not a nucleoside analogue and has a higher specificity for xanthine oxidase. Although this drug
Matt Bohm, Naga Chalasani, null null, Raj Vuppalanchi   +3 more
core   +2 more sources

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression

PLoS ONE, 2022
Background Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable.
Seokwoo Park, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim, Chun Soo Lim   +4 more
doaj   +3 more sources